Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3
Abstract
The administration of human biotherapeutics is often associated with a higher incidence of immunogenicity in preclinical species. The presence of anti-drug antibodies (ADAs) in the test samples can affect the accurate measurement of therapeutic protein (TP) in bioanalytical methods designed to support pharmacokinetic (PK) and toxicokinetic (TK) assessments. The impact can vary depending on the bioanalytical method platform and study dosing design. The goal of this study is to evaluate the impact of ADA response on the bioanalytical methods in support of PK/TK and the associated study data interpretation. Sprague Dawley rats were administered with four weekly doses of 50 mg/kg TP, a humanized monoclonal antibody. The TP in serum samples was measured using three bioanalytical methods that quantified bound and/or unbound TP to ADA. The ADA response in the animals was classified into negative, low, medium, and high based on the magnitude of the response. The presence of ADA in samples led to discrepant TP measurements between the methods, especially at time points where the TP concentrations were low. This could be due to ADA interference to the accurate measurement of ADA-bound TP concentrations. The TP concentration at last time point (Clast) was reduced by 82.8%, 98.6%, and 99.8%, respectively, for samples containing low, medium, and high levels of ADA. The interfering effects of the ADA on bioanalytical methods and exposure were evident as early as 2 weeks post-dosing. This modeling approach can provide the better understanding of ADA impact on PK exposure in multiple doses.
Authors and Affiliations
Theingi M. Thway, Ivan Magana, Ami Bautista, Vibha Jawa, Wen Gu, Mark Ma
Keywords
Related Articles
- EP ID EP681140
- DOI 10.1208/s12248-013-9484-4
- Views 60
- Downloads 0
Effect of Device Design on the Aerosolization of a Carrier-Based Dry Powder Inhaler—a Case Study on Aerolizer® Foradile®
The objective of this study is to investigate the effect of device design of the Aerolizer® on the aerosolization of a carrier-based dry powder inhaler formulation (Foradile®). The Aerolizer was modified...
Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies
The online version of this article (doi:10.1208/s12248-014-9661-0) contains supplementary material, which is available to authorized users.
Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats
Biochanin A(BCA) is a dietary isoflavone present in legumes, most notably red clover, and in many herbal dietary supplements. BCA has been reported to have chemopreventive properties and is metabolized to the isoflavone...
Challenges in the transition to model-based development
Pulmonary Immunization of Guinea Pigs with Diphtheria CRM-197 Antigen as Nanoparticle Aggregate Dry Powders Enhance Local and Systemic Immune Responses
This study establishes the immune response elicited in guinea pigs after pulmonary and parenteral immunizations with diphtheria CRM-197 antigen (CrmAg). Several spray-dried powders of formalin-treated/untreated CrmAg nan...